<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2003-1128</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-1046</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Кофактор антилипидных антител при сифилисе, боррелиозе Лайма и аутоиммунных заболеваниях</article-title><trans-title-group xml:lang="en"><trans-title>Antilipide antibodies cofactor in syphilis, Lyme borreliosis and autoimmune diseases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Voicechovskaya</surname><given-names>B</given-names></name><name name-style="western" xml:lang="en"><surname>Voicechovskaya</surname><given-names>B</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лаборатория микробиологии и серологии</p></bio><bio xml:lang="en"><p>Laboratoriya mikrobiologii i serologii</p></bio><email xlink:type="simple">-</email></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Zabek</surname><given-names>J</given-names></name><name name-style="western" xml:lang="en"><surname>Zabek</surname><given-names>J</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лаборатория микробиологии и серологии</p></bio><bio xml:lang="en"><p>Laboratoriya mikrobiologii i serologii</p></bio><email xlink:type="simple">-</email></contrib></contrib-group><pub-date pub-type="collection"><year>2003</year></pub-date><pub-date pub-type="epub"><day>15</day><month>02</month><year>2003</year></pub-date><volume>41</volume><issue>1</issue><issue-title>№1 (2003)</issue-title><fpage>24</fpage><lpage>26</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Voicechovskaya B., Zabek J., 2003</copyright-statement><copyright-year>2003</copyright-year><copyright-holder xml:lang="ru">Voicechovskaya B., Zabek J.</copyright-holder><copyright-holder xml:lang="en">Voicechovskaya B., Zabek J.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/1046">https://rsp.mediar-press.net/rsp/article/view/1046</self-uri><abstract><p>Цель. Изучить вклад ?2 - гликопротеина 1 в выявляемость аКЛ у больных с аутоиммунными и некоторыми инфекционными заболеваниями. Материал и методы. Иммуноферментным методом (ИФМ) были исследованы антитела к различным видам фосфолипидов в сыворотках 92 больных: 20 - с системной красной волчанкой (СКВ), 15 - с болезнью Шегрена (БШ), 20 - с ревматоидным артритом (РА), 20 - с сифилисом и 17 - с болезнью Лайма (БЛ). У больных с сифилисом и БЛ клинические признаки аутоиммунного заболевания отсутствовали. Стимулирование теста аКЛ в ИФМ проводилось после предварительной инкубации кардиолипина на микротитрованных пластинках с использованием электрофоретически чистого (52 - гликопротеина 1. Результаты. Наиболее часто аФЛ выявлялись в сыворотках больных СКВ и сифилисом, реже при БШ. В аКЛ-позитивных сыворотках обнаруживались антитела к некоторым другим фосфолипидам. Средние значения стимулированного теста аКЛ в ИФМ после предварительной инкубации с чистым (32 - гликопротеином 1 были выше при аутоиммунных заболеваниях, чем при инфекционных. Заключение. Разделение аКЛ на кофактор "зависимый" и "независимый" или аутоиммунный и инфекционный тип не представляется окончательным.</p></abstract><trans-abstract xml:lang="en"><p>Objective. To study (32 glycoprotein 1 contribution to frequency of aCL in pts with autoimmune and some infectious diseases. Methods. Antibodies to different phospholipids were tested by immune-enzyme method (IEM) in serum of 92 pts: 20 of them had systemic lupus erythematosus (SLE), 15 Sjogren’s disease (SD), 20 rheumatoid arthritis (RA), 20 syphilis and 17 Lyme disease (LD). Pts with syphilis and LD did not have clinical signs of autoimmune disease. Stimulation of aCL test in IEM was performed after previous cardiolipin incubation on microtitrated plates with electrophoretic pure p2 glycoprotein 1. Results. aCL were mostly revealed in serum of patients with SLE and syphilis, less often in SD. In aCL- positive serums antibodies to some other phospholipids were found. Mean values of stimulating aCL test in IEM after previous incubation with pure |32-glycoprotein 1 in autoimmune diseases were higher than in infection. aCL division into cofactor «dependent» and «independent» or autoimmune and infectious types seems to be not final.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>Кофактор антилипидных антител</kwd><kwd>Лайм боррелиоз</kwd><kwd>сифилис</kwd><kwd>аутоиммунные заболевания</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">&lt;div&gt;&lt;p&gt;Alarcon-Segivia D. Clinical manifestations of the antiphos- pholoipid syndrome. J. Rheumatol. 1992, 19. 1778-1781&lt;/p&gt;&lt;p&gt;Asherson R.A., Cervera R. "Primary", secondary and orther variants of the antiphospholipid syndrome. Lupus, 1994, 3, 293-298.&lt;/p&gt;&lt;p&gt;Costello PB, Green F.A. Reactivity patterns of human anti- cardiolipin and other antiphospholipid antibodies in syphilitic sera. Infect. Immun. 1986, 51, 771-775.&lt;/p&gt;&lt;p&gt;Gharavi A.E., Harris E.N., Asherson R.A,. Hughes GRV. Antiphospholipid antibodies: isotype distribution and phospholipid specificity. Ann. Rheum. Dis. 1987, 46, 1-6.&lt;/p&gt;&lt;p&gt;Gharavi A.E., Pierangeli SS. Origin of antiphospholipid antibodies: induction of aPL by viral peptides. Lupus, 1998, 7, S211&lt;/p&gt;&lt;p&gt;Harris E.N., Gharavi A.E., Wasley G.D., Hughes G.R.V. Use of enzyme-linked assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders. J. Infect. Dis. 1988, 157, 23-31.&lt;/p&gt;&lt;p&gt;Hunt J., Krilis S. A phospholipid- p2-glywcoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with ifection. Lupus, 1992, 1, 75-81.&lt;/p&gt;&lt;p&gt;Kandiah D.A., Krilis S.A. Immunology and methods of detection of antiphopspholipid antibodies. In: Asherson RA., Cervera R., Piette J.C., Shoenfeld Y. (eds) The antiphospholipid syndrome. CRC Press, USA, 1996, 29&lt;/p&gt;&lt;p&gt;Lopez-Soto A., Cervera R., Font J. Isotype distribution and clinical significance of antibodies to cardiolipin , phosphat- ic acid, phosphatydilinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients. Clin. Experimental. 1997, 15, 143-149.&lt;/p&gt;&lt;p&gt;Luft S. Metody diagnostyki serologicznej w reumatologii. Widawnictwo naukowe PWN, Warszawa. 1996, 101-102.&lt;/p&gt;&lt;p&gt;McNeil H.P., Chesterman C.N., Krilis S.A. Immunology and clinical importance of antiphospholipid antibodies. Adv. Immunol. 1991, 49, 193-280.&lt;/p&gt;&lt;p&gt;McNeil H.P., Chesterman C.N., Krilis SA. Anticardiolipin antibodies and lupus anticoagulant separate antibody subgroups with different phospholipid binding characteristics. Br.J. Haematol. 1989, 73,506.&lt;/p&gt;&lt;p&gt;Poltz E, Kostner G.M. FEBS Letters. 1979, 102, 183.&lt;/p&gt;&lt;p&gt;Решетник TM,. Б.Войцеховская, З.САпекберова, и др. Антитела к различным фосфолипидам у больных системной красной волчанкой и первичным антифосфо- липидным синдромом. Клинич. Мед. 1999, 5, 32-37.&lt;/p&gt;&lt;p&gt;Reshetniak TM, B.Wojciechowska, Z.Alekberova, et al. Korelacia wystepowania surowiczych przeciwcial antyfos- folipidowych oraz anticoagulantu tocznia z wybranymi objawami klinicznymi u chorych z toczeniem rumieniowatym ukladowym oraz pierwotnym i wtomym zespolem antyfosfolipidowym. Reumatologia 1999, 37, (2) 145-147&lt;/p&gt;&lt;p&gt;Loizou S.A., Walport M.A., Davies K.A. The antiphospholipid syndrome and infectious diseases. In Asherson R.A., Cervera R., Piette J.C., Shoenfeld Y. (eds) The antiphospholipid syndrome. CRC Press, USA, 1996, 267-287. *&lt;/p&gt;&lt;p&gt;Weidmann C.E., Wallanca D.J., Peter J.B., et al. Studies of IgG, IgM, and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol. 1993, 20, 1598-1600. •&lt;/p&gt;&lt;p&gt;Shelley W.B., Shelley E.D. Syphilis. In : Advanced Dermatologic Diagnoses. WB Saunders: Philadelfia, RA, 1992, 1183-1187.&lt;/p&gt;&lt;p&gt;Zabek J., Luft S., Woiciechowska B., Biemacka E. et al. Badania nad krzywa reakty wicoscia przeciwciab antifos- folipidowych w ukladowych chorobach tkanki lacznej. Reumatologia, 1995, 33 (2), 112&lt;/p&gt;&lt;p&gt;Zabek J., Woiciechowska B., Luft S. The study on the significance of the apolipoprotein H as an autoantigen and a cofactor or the specific antiphospholipids antibodies reactions. Reumatologia, 1998, 36, 55, 147.&lt;/p&gt;&lt;/div&gt;&lt;br /&gt;</mixed-citation><mixed-citation xml:lang="en">&lt;div&gt;&lt;p&gt;Alarcon-Segivia D. Clinical manifestations of the antiphos- pholoipid syndrome. J. Rheumatol. 1992, 19. 1778-1781&lt;/p&gt;&lt;p&gt;Asherson R.A., Cervera R. "Primary", secondary and orther variants of the antiphospholipid syndrome. Lupus, 1994, 3, 293-298.&lt;/p&gt;&lt;p&gt;Costello PB, Green F.A. Reactivity patterns of human anti- cardiolipin and other antiphospholipid antibodies in syphilitic sera. Infect. Immun. 1986, 51, 771-775.&lt;/p&gt;&lt;p&gt;Gharavi A.E., Harris E.N., Asherson R.A,. Hughes GRV. Antiphospholipid antibodies: isotype distribution and phospholipid specificity. Ann. Rheum. Dis. 1987, 46, 1-6.&lt;/p&gt;&lt;p&gt;Gharavi A.E., Pierangeli SS. Origin of antiphospholipid antibodies: induction of aPL by viral peptides. Lupus, 1998, 7, S211&lt;/p&gt;&lt;p&gt;Harris E.N., Gharavi A.E., Wasley G.D., Hughes G.R.V. Use of enzyme-linked assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders. J. Infect. Dis. 1988, 157, 23-31.&lt;/p&gt;&lt;p&gt;Hunt J., Krilis S. A phospholipid- p2-glywcoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with ifection. Lupus, 1992, 1, 75-81.&lt;/p&gt;&lt;p&gt;Kandiah D.A., Krilis S.A. Immunology and methods of detection of antiphopspholipid antibodies. In: Asherson RA., Cervera R., Piette J.C., Shoenfeld Y. (eds) The antiphospholipid syndrome. CRC Press, USA, 1996, 29&lt;/p&gt;&lt;p&gt;Lopez-Soto A., Cervera R., Font J. Isotype distribution and clinical significance of antibodies to cardiolipin , phosphat- ic acid, phosphatydilinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients. Clin. Experimental. 1997, 15, 143-149.&lt;/p&gt;&lt;p&gt;Luft S. Metody diagnostyki serologicznej w reumatologii. Widawnictwo naukowe PWN, Warszawa. 1996, 101-102.&lt;/p&gt;&lt;p&gt;McNeil H.P., Chesterman C.N., Krilis S.A. Immunology and clinical importance of antiphospholipid antibodies. Adv. Immunol. 1991, 49, 193-280.&lt;/p&gt;&lt;p&gt;McNeil H.P., Chesterman C.N., Krilis SA. Anticardiolipin antibodies and lupus anticoagulant separate antibody subgroups with different phospholipid binding characteristics. Br.J. Haematol. 1989, 73,506.&lt;/p&gt;&lt;p&gt;Poltz E, Kostner G.M. FEBS Letters. 1979, 102, 183.&lt;/p&gt;&lt;p&gt;Решетник TM,. Б.Войцеховская, З.САпекберова, и др. Антитела к различным фосфолипидам у больных системной красной волчанкой и первичным антифосфо- липидным синдромом. Клинич. Мед. 1999, 5, 32-37.&lt;/p&gt;&lt;p&gt;Reshetniak TM, B.Wojciechowska, Z.Alekberova, et al. Korelacia wystepowania surowiczych przeciwcial antyfos- folipidowych oraz anticoagulantu tocznia z wybranymi objawami klinicznymi u chorych z toczeniem rumieniowatym ukladowym oraz pierwotnym i wtomym zespolem antyfosfolipidowym. Reumatologia 1999, 37, (2) 145-147&lt;/p&gt;&lt;p&gt;Loizou S.A., Walport M.A., Davies K.A. The antiphospholipid syndrome and infectious diseases. In Asherson R.A., Cervera R., Piette J.C., Shoenfeld Y. (eds) The antiphospholipid syndrome. CRC Press, USA, 1996, 267-287. *&lt;/p&gt;&lt;p&gt;Weidmann C.E., Wallanca D.J., Peter J.B., et al. Studies of IgG, IgM, and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol. 1993, 20, 1598-1600. •&lt;/p&gt;&lt;p&gt;Shelley W.B., Shelley E.D. Syphilis. In : Advanced Dermatologic Diagnoses. WB Saunders: Philadelfia, RA, 1992, 1183-1187.&lt;/p&gt;&lt;p&gt;Zabek J., Luft S., Woiciechowska B., Biemacka E. et al. Badania nad krzywa reakty wicoscia przeciwciab antifos- folipidowych w ukladowych chorobach tkanki lacznej. Reumatologia, 1995, 33 (2), 112&lt;/p&gt;&lt;p&gt;Zabek J., Woiciechowska B., Luft S. The study on the significance of the apolipoprotein H as an autoantigen and a cofactor or the specific antiphospholipids antibodies reactions. Reumatologia, 1998, 36, 55, 147.&lt;/p&gt;&lt;/div&gt;&lt;br /&gt;</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
